ONEVAX
MILESTONES
2012
Formation of OneVax, LLC.
2013
1st SBIR phase I grant awarded: R43 DK100132, NIDDK, “Polymeric Biomaterial-based microparticle vaccine for the amelioration of Type 1 Diabetes”
2014
2nd SBIR phase I grant awarded: R43 DK103402-01A1, NIDDK, “A novel biomaterial-based therapy to prevent type 1 diabetes”
2017
3rd SBIR phase 1 grant awarded: R43 AI29034-01, NIAID, “A novel biomaterial-based therapy utilizing auto-antigen and adjuvant for the amelioration of Type 1 Diabetes”
Approval of funding for the partnered project entitled “Investigating a novel biomaterial-based therapy utilizing auto-antigen and adjuvant for the amelioration of Type I Diabetes” by The Florida High Tech Corridor Councils Matching Grants Program based at the University of Florida.
4th SBIR phase 1 awarded: R43 AI131850-01, NIAID, “Biomaterial-based delivery of Interleukin-2 to Regulatory T Cells for the amelioration of Type 1 Diabetes”
1st R21 grant awarded: R21 AI133067-01, NIAID, “Delivery of biomaterial-conjugated regulatory T cells for the amelioration of Type 1 Diabetes”
1st STTR Phase 1 grant awarded: 1R41AI134213-01, NIAID, “Therapeutic Administration of Suppressor of Cytokine Signaling Mimetics to Ameliorate Type 1 Diabetes”
2018
5th SBIR Phase 1 grant awarded: 1R43AI140929-01, NIAID,”Development of a dual microparticle platform vaccine system encapsulating immunomodulatory agents and antigen for the amelioration of type 1 diabetes”